Impact of the Novel 5-Group Cytogenetic Risk Classification of MDS on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT)

被引：3
|
作者：
Deeg, H. Joachim [1 ]
Scott, Bart Lee [1 ,2 ]
Appelbaum, Frederick R. [1 ]
Gooley, Ted [1 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[2] Univ Washington, Seattle, WA 98195 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.666.666
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：306 / 307
页数：2
相关论文
共 50 条
  • [1] THE NOVEL 5-GROUP CYTOGENETIC RISK CLASSIFICATION OF MYELO-DYSPLASTIC SYNDROME (MDS), MONOSOMAL KARYOTYPE, AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
    Gerds, A.
    Gooley, T.
    Scott, B. L.
    Appelbaum, F. R.
    Deeg, H. F.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S212 - S212
  • [2] New cytogenetic abnormalities are frequent in AML and MDS relapsing after allogeneic hematopoietic cell transplantation (HCT).
    Pollyea, Daniel A.
    Artz, Andrew S.
    Stock, Wendy
    Daugherty, Christopher
    Godley, Lucy
    Odenike, Olatoyosi M.
    Rich, Elizabeth
    Smith, Sonali M.
    Zimmerman, Todd
    Zhang, Yanming
    Huo, Dezheng
    Larson, Richard
    Van Besien, Koen
    BLOOD, 2006, 108 (11) : 1050A - 1050A
  • [3] Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS
    Deeg, H. Joachim
    Scott, Bart L.
    Fang, Min
    Shulman, Howard M.
    Gyurkocza, Boglarka
    Myerson, David
    Pagel, John M.
    Platzbecker, Uwe
    Ramakrishnan, Aravind
    Radich, Jerald P.
    Sandmaier, Brenda M.
    Sorror, Mohamed
    Stirewalt, Derek L.
    Wilson, Wendy A.
    Storb, Rainer
    Appelbaum, Frederick R.
    Gooley, Ted
    BLOOD, 2012, 120 (07) : 1398 - 1408
  • [4] Allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic syndrome (MDS) after pretransplant 5-azacitidine
    Field, Teresa
    Alsina, Melissa
    Ayala, Ernesto
    Fernandez, Hugo
    Janssen, William
    Karfan-Dabaja, Mohammed
    Lancer, Jeffery
    Melchert, Mafda
    Raychaudhuri, Jyoti
    Sullivan, Daniel
    List, Alan
    Anasetti, Claudio
    Poling, William
    Perkins, Janelle
    BLOOD, 2007, 110 (11) : 338B - 338B
  • [5] Long-term outcome after allogeneic hematopoietic cell transplantation (HCT) for CML
    Goldman, JM
    Sobocinski, KA
    Zhang, MJ
    Klein, JP
    Ketelsen, SW
    Giralt, SA
    Horowitz, MM
    Rizzo, JD
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 17 - 17
  • [6] Impact of Comorbidities on Early and Late Mortalities After Allogeneic Hematopoietic Cell Transplantation (HCT)
    Sorror, Mohamed L.
    Storb, Rainer
    Sandmaier, Brenda M.
    Bhatia, Smita
    Maziarz, Richard T.
    Pulsipher, Michael A.
    Maris, Michael T.
    Deeg, H. Joachim
    Appelbaum, Frederick R.
    Maloney, David G.
    Martin, Paul J.
    Storer, Barry
    BLOOD, 2011, 118 (21) : 153 - 153
  • [7] Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)
    Hamilton, Betty Ky
    Rybicki, Lisa
    Gerds, Aaron
    Hanna, Rabi
    Sobecks, Ronald
    Hien Duong
    Starn, Jamie
    Corbett, Elaina
    Bolwell, Brian
    Majhail, Navneet S.
    Kalaycio, Matt E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S226 - S227
  • [8] Impact of Donor Age on Outcome after Allogeneic Hematopoietic Cell Transplantation
    Rezvani, Andrew R.
    Storer, Barry E.
    Guthrie, Katherine A.
    Schoch, H. Gary
    Maloney, David G.
    Sandmaier, Brenda M.
    Storb, Rainer
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (01) : 105 - 112
  • [9] IMPROVED OUTCOME OF ELDERLY PATIENTS AFTER REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
    Avraham, Perets G.
    Bains, T.
    Lemieux, A.
    Slater, S.
    Kovacsovics, T.
    Curtin, P.
    Gajewski, J.
    Meyers, G.
    Maziarz, R. T.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S347 - S348
  • [10] Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL
    Rahman, Zaid H. Abdel
    Heckman, Michael G.
    Miller, Kevin
    Alkhateeb, Hassan
    Patnaik, Mrinal S.
    Sproat, Lisa Z.
    Jiang, Liuyan
    Roy, Vivek
    Murthy, Hemant S.
    Ayala, Ernesto
    Hogan, William J.
    Greipp, Patricia T.
    Kharfan-Dabaja, Mohamed A.
    Litzow, Mark R.
    Foran, James M.
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (02): : 165.e1 - 165.e11
12345